This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (55)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Cognitive Disorders  • Alert me on articles by topic

William R. Markesbery, MD; Frederick A. Schmitt, PhD; Richard J. Kryscio, PhD; Daron G. Davis, MD; Charles D. Smith, MD; David R. Wekstein, PhD

Arch Neurol. 2006;63:38-46.

Objective  To define the neuropathologic findings in amnestic mild cognitive impairment (MCI) and early Alzheimer disease (EAD).

Methods  The mean numbers of diffuse plaques, neuritic plaques (NPs), and neurofibrillary tangles (NFTs) in 4 neocortical regions and 4 ventromedial temporal lobe regions were counted in 10 patients with amnestic MCI and compared with the mean numbers in 23 normal control subjects and 10 patients with EAD, and then were compared with memory performance. All of the controls and patients were followed longitudinally.

Results  Patients with MCI showed no significant difference (P>.05) in the number of diffuse plaques from that in normal controls or patients with EAD. In patients with MCI, the number of NPs was significantly elevated in all 4 neocortical regions and amygdala compared with controls (P<.01 to <.001). There were no significant differences (P>.05) in the number of NPs between MCI and EAD cerebral cortex, but significant increases were present for NPs in EAD amygdala and subiculum compared with MCI (P<.01). In patients with MCI compared with controls, the only significant increase in NFTs in the neocortex was in the parietal lobe. However, the number of NFTs was significantly elevated in MCI in all 4 ventromedial temporal lobe structures compared with controls (P<.01 to <.001). In comparing MCI with EAD, there were significant increases in NFTs in EAD in frontal and temporal lobes, amygdala, and subiculum (P<.01). The numbers of NPs and NFTs were significantly elevated in all of the neocortical regions and ventromedial temporal lobe regions in patients with EAD compared with controls (P<.001). Memory function was significantly correlated with NFTs in CA1 of the hippocampus (P<.01) and the entorhinal cortex (P<.05).

Conclusions  In patients with amnestic MCI who were followed longitudinally, the early changes of Alzheimer disease were present. The NFTs were slightly more prominent than -amyloid peptide deposition in the progression from normal to MCI to EAD. Ventromedial temporal lobe NFTs probably represent the substrate for memory decline in MCI. From a neuropathologic perspective, it appears that amnestic MCI is, in reality, EAD.

Author Affiliations: Alzheimer’s Disease Center, Sanders-Brown Center on Aging (Drs Markesbery, Schmitt, Kryscio, Smith, and Wekstein), and Departments of Neurology (Drs Markesbery, Schmitt, and Smith), Pathology (Drs Markesbery and Davis), Statistics and Public Health (Dr Kryscio), and Physiology (Dr Wekstein), University of Kentucky, Lexington.

RELATED ARTICLE

Mild Cognitive Impairment Is Early-Stage Alzheimer Disease: Time to Revise Diagnostic Criteria
John C. Morris
Arch Neurol. 2006;63(1):15-16.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

An aberrant protein complex in CSF as a biomarker of Alzheimer disease
Lovell et al.
Neurology 2008;70:2212-2218.
ABSTRACT | FULL TEXT  

Fear conditioning in frontotemporal lobar degeneration and Alzheimer's disease
Hoefer et al.
Brain 2008;131:1646-1657.
ABSTRACT | FULL TEXT  

Safety and efficacy of galantamine in subjects with mild cognitive impairment
Winblad et al.
Neurology 2008;70:2024-2035.
ABSTRACT | FULL TEXT  

Mild Cognitive Impairment: Challenging Issues
Ganguli and Petersen
AJGP 2008;16:339-342.
FULL TEXT  

Facial Emotion Recognition Deficit in Amnestic Mild Cognitive Impairment and Alzheimer Disease
Spoletini et al.
AJGP 2008;16:389-398.
ABSTRACT | FULL TEXT  

Change in Depressive Symptoms During the Prodromal Phase of Alzheimer Disease
Wilson et al.
Arch Gen Psychiatry 2008;65:439-445.
ABSTRACT | FULL TEXT  

Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease
Lovell and Markesbery
Nucleic Acids Res 2007;35:7497-7504.
ABSTRACT | FULL TEXT  

Clinical Prediction of Alzheimer Disease Dementia Across the Spectrum of Mild Cognitive Impairment
Dickerson et al.
Arch Gen Psychiatry 2007;64:1443-1450.
ABSTRACT | FULL TEXT  

{beta}-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
Pike et al.
Brain 2007;130:2837-2844.
ABSTRACT | FULL TEXT  

Disease-modifying therapies for Alzheimer disease: Challenges to early intervention
Cummings et al.
Neurology 2007;69:1622-1634.
ABSTRACT | FULL TEXT  

PIB is a non-specific imaging marker of amyloid-beta (A{beta}) peptide-related cerebral amyloidosis
Lockhart et al.
Brain 2007;130:2607-2615.
ABSTRACT | FULL TEXT  

Olfactory Identification and Incidence of Mild Cognitive Impairment in Older Age
Wilson et al.
Arch Gen Psychiatry 2007;64:802-808.
ABSTRACT | FULL TEXT  

Chronic distress and incidence of mild cognitive impairment
Wilson et al.
Neurology 2007;68:2085-2092.
ABSTRACT | FULL TEXT  

PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment
Kemppainen et al.
Neurology 2007;68:1603-1606.
ABSTRACT | FULL TEXT  

Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment
Scheff et al.
Neurology 2007;68:1501-1508.
ABSTRACT | FULL TEXT  

Brain structural alterations before mild cognitive impairment
Smith et al.
Neurology 2007;68:1268-1273.
ABSTRACT | FULL TEXT  

Activation of Caspase-6 in Aging and Mild Cognitive Impairment
Albrecht et al.
Am. J. Pathol. 2007;170:1200-1209.
ABSTRACT | FULL TEXT  

Mild cognitive impairment: Risk of Alzheimer disease and rate of cognitive decline
Panza et al.
Neurology 2007;68:964-965.
FULL TEXT  

Cortical biochemistry in MCI and Alzheimer disease: Lack of correlation with clinical diagnosis
Forman et al.
Neurology 2007;68:757-763.
ABSTRACT | FULL TEXT  

Incidence of Dementia in Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study
Lopez et al.
Arch Neurol 2007;64:416-420.
ABSTRACT | FULL TEXT  

Cerebrospinal Fluid tau/beta-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults
Fagan et al.
Arch Neurol 2007;64:343-349.
ABSTRACT | FULL TEXT  

Pathologic and Nicotinic Receptor Binding Differences Between Mild Cognitive Impairment, Alzheimer Disease, and Normal Aging
Sabbagh et al.
Arch Neurol 2006;63:1771-1776.
ABSTRACT | FULL TEXT  

Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease
Singh et al.
Brain 2006;129:2885-2893.
ABSTRACT | FULL TEXT  

Mild Cognitive Impairment Should Be Considered for DSM-V
Petersen and O'Brien
J Geriatr Psychiatry Neurol 2006;19:147-154.
ABSTRACT  

Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI
Storandt et al.
Neurology 2006;67:467-473.
ABSTRACT | FULL TEXT  

Mild Cognitive Impairment: Looks Like AD
JWatch Psychiatry 2006;2006:3-3.
FULL TEXT  

Mild Cognitive Impairment Is Early-Stage Alzheimer Disease: Time to Revise Diagnostic Criteria
Morris
Arch Neurol 2006;63:15-16.
FULL TEXT